Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Phase II results for temozolomide in non-small cell lung cancer reported

Feb. 6, 2009

NVP-BEZ-235 a candidate for ovarian cancer treatment

Feb. 6, 2009

New Aurora B kinase inhibitors reported in recent Boehringer Ingelheim patent

Feb. 6, 2009

Isoform-selective phospholipase D inhibitors developed at Vanderbilt University

Feb. 5, 2009

JMR-132, AN-162 demonstrate ovarian tumor growth inhibition in xenograft models

Feb. 5, 2009

Abraxis BioScience launches Abraxane in Germany

Feb. 5, 2009

OncoGenex provides 2-year survival data from ongoing OGX-011 trial

Feb. 5, 2009

Allos reports results from pivotal pralatrexate trial in peripheral T-cell lymphoma

Feb. 5, 2009

Pfizer's Sutent is recommended as first-line treatment for kidney cancer

Feb. 5, 2009

Boehringer Ingelheim claims new oncolytic PI3K inhibitors in recent patent

Feb. 5, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...